32 Biosciences

32 Biosciences is a private, pre-revenue biotech developing first-in-class therapeutics and a discovery platform targeting the gut mucosal-immune system. Its lead asset, CS-0003, is a Mucosal Immune Modulator (MIM) aimed at preventing GI surgical site infections, with a planned Phase II trial supported by an upcoming $40M Series A round. The company's core technology measures metabolomic signatures of the gut mucosal-immune system to enable therapeutic discovery and clinical decision support across multiple GI indications.

GI Discovery Platform that measures metabolomic signatures of the gut mucosal-immune system to enable therapeutic discovery, development, and clinical decision support.

32 Biosciences operates in the competitive microbiome and GI therapeutics space, but differentiates by focusing specifically on the metabolomic signatures of the gut mucosal-immune interface, a niche less crowded than broader microbiome modulation. It faces competition from large pharma with IBD portfolios and other biotechs targeting gut barrier function.